Association between macrophage migration inhibitory factor promoter region polymorphism (-173 G/C) and cancer: A meta-analysis

BMC Research Notes

Volumn 4, Issue , 2011, Pages

  Vera, Pedro L ^a,b   Meyer Siegler, Katherine L ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 83455169114     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-4-395     Document Type: Article

References (41)

1. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Bloom BR, Bennett B, Science 1966 153 731 80 2 10.1126/science.153.3731.80 5938421
2. Macrophage migration inhibitory factor. Baugh JA, Bucala R, Crit Care Med 2002 30 1 Supp 27 S35 11891404
3. Macrophage migration inhibitory factor (MIF): a promising biomarker. Grieb G, Merk M, Bernhagen J, Bucala R, Drug News Perspect 2010 23 4 257 264 10.1358/dnp.2010.23.4.1453629 20520854
4. Macrophage migration inhibitory factor activates antigen-presenting dendritic cells and induces inflammatory cytokines in ulcerative colitis. Murakami H, Akbar SM, Matsui H, Horiike N, Onji M, Clin Exp Immunol 2002 128 3 504 10 10.1046/j.1365-2249.2002.01838.x 12109441 (Pubitemid 34639313)
5. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. Al-Abed Y, Dabideen D, Aljabari B, Valster A, Messmer D, Ochani M, Tanovic M, Ochani K, Bacher M, Nicoletti F, Metz C, Pavlov VA, Miller EJ, Tracey KJ, JBC 2005 280 44 36541 4 10.1074/jbc.C500243200 (Pubitemid 41587728)
6. Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Leech M, Metz C, Hall P, Hutchinson P, Gianis K, Smith M, Weedon H, Holdsworth SR, Bucala R, Morand EF, Arthritis Rheum 1999 42 8 1601 8 10.1002/1529-0131(199908)42: 8<1601::AID-ANR6>3.0.CO;2-B 10446857 (Pubitemid 30263626)
7. Urine macrophage migration inhibitory factor concentrations as a diagnostic tool in human renal allograft rejection. Brown FG, Nikolic-Paterson DJ, Chadban SJ, Dowling J, Jose M, Metz CN, Bucala R, Atkins RC, Transplantation 2001 71 12 1777 83 10.1097/00007890-200106270-00013 11455258 (Pubitemid 32622490)
8. Development of chronic colitis is dependent on the cytokine MIF. de Jong YP, Abadia-Molina AC, Satoskar AR, Clarke K, Rietdijk ST, Faubion WA, Mizoguchi E, Metz CN, Alsahli M, ten Hove T, Keates AC, Lubetsky JB, Farrell RJ, Michetti P, van Deventer SJ, Lolis E, David JR, Bhan AK, Terhorst C, Nat Immunol 2001 2 11 1061 6 10.1038/ni720 11668338 (Pubitemid 33069502)
9. Macrophage migration inhibitory factor is an important mediator in the pathogenesis of gastric inflammation in rats. Huang XR, Chun Hui CW, Chen YX, Wong BC, Fung PC, Metz C, Cho CH, Hui WM, Bucala R, Lam SK, Lan HY, Chun B, Wong Y, Gastroenterology 2001 121 3 619 30 10.1053/gast.2001.27205 11522746 (Pubitemid 32822577)
10. Cancer and inflammation: implications for pharmacology and therapeutics. Balkwill F, Mantovani A, Clin Pharmacol Ther 2010 87 4 401 406 10.1038/clpt.2009.312 20200512
11. Inflammation and cancer: macrophage migration inhibitory factor (MIF)-the potential missing link. Conroy H, Mawhinney L, Donnelly SC, QJM 2010 103 11 831 836 10.1093/qjmed/hcq148 20805118
12. Expression of macrophage migration inhibitory factor in the human prostate. Meyer-Siegler K, Fattor RA, Hudson PB, Diagnostic molecular pathology: the American journal of surgical pathology, part B 1998 7 44 50 10.1097/00019606-199802000-00008 (Pubitemid 28285810)
13. Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma. Meyer-Siegler KL, Bellino MA, Tannenbaum M, Cancer 2002 94 1449 56 10.1002/cncr.10354 11920501 (Pubitemid 34212639)
14. Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer. Meyer-Siegler KL, Iczkowski KA, Vera PL, BMC cancer 2005 5 73 10.1186/1471-2407-5-73 16000172 (Pubitemid 41461059)
15. Macrophage migration inhibitory factor in prostatic adenocarcinoma: correlation with tumor grading and combination endocrine treatment-related changes. del Vecchio MT, Tripodi SA, Arcuri F, Pergola L, Hako L, Vatti R, Cintorino M, The Prostate 2000 45 51 7 10.1002/1097-0045(20000915)45:1<51:: AID-PROS6>3.0.CO;2-9 10960842
16. Regulation of human lung adenocarcinoma cell migration and invasion by macrophage migration inhibitory factor. Rendon BE, Roger T, Teneng I, Zhao M, Al-Abed Y, Calandra T, Mitchell RA, J Biol Chem 2007 282 41 29910 8 10.1074/jbc.M704898200 17709373 (Pubitemid 350035289)
17. Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer. Verjans E, Noetzel E, Bektas N, Schutz AK, Lue H, Lennartz B, Hartmann A, Dahl E, Bernhagen J, BMC cancer 2009 9 230 10.1186/1471-2407-9-230 19602265
18. Macrophage migration inhibitory factor promotes intestinal tumorigenesis. Wilson JM, Coletta PL, Cuthbert RJ, Scott N, MacLennan K, Hawcroft G, Leng L, Lubetsky JB, Jin KK, Lolis E, Medina F, Brieva JA, Poulsom R, Markham AF, Bucala R, Hull MA, Gastroenterology 2005 129 5 1485 503 10.1053/j.gastro.2005.07.061 16285950 (Pubitemid 41597391)
19. Macrophage migration inhibitory factor in cancer. Yasasever V, Camlica H, Duranyildiz D, Oguz H, Tas F, Dalay N, Cancer Invest 2007 25 8 715 9 10.1080/07357900701560695 18058468 (Pubitemid 350223175)
20. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Baugh JA, Chitnis S, Donnelly SC, Monteiro J, Lin X, Plant BJ, Wolfe F, Gregersen PK, Bucala R, Genes and immunity 2002 3 3 170 6 10.1038/sj.gene. 6363867 12070782 (Pubitemid 38961128)
21. A functional promoter haplotype of macrophage migration inhibitory factor is linked and associated with juvenile idiopathic arthritis. Donn R, Alourfi Z, Zeggini E, Lamb R, Jury F, Lunt M, Meazza C, De Benedetti F, Thomson W, Ray D, Arthritis Rheum 2004 50 5 1604 10 10.1002/art.20178 15146431 (Pubitemid 38608083)
22. A novel 5'-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Donn RP, Shelley E, Ollier WE, Thomson W, Arthritis Rheum 2001 44 8 1782 5 10.1002/1529-0131(200108)44:8<1782::AID-ART314>3.0.CO;2-# 11508429 (Pubitemid 32758224)
23. Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Donn R, Alourfi Z, De Benedetti F, Meazza C, Zeggini E, Lunt M, Stevens A, Shelley E, Lamb R, Ollier WE, Thomson W, Ray D, Arthritis Rheum 2002 46 9 2402 9 10.1002/art.10492 12355488
24. Association between functional promoter polymorphisms of macrophage migration inhibitory factor (MIF) gene and ulcerative colitis in Japan. Shiroeda H, Tahara T, Nakamura M, Shibata T, Nomura T, Yamada H, Hayashi R, Saito T, Yamada M, Fukuyama T, Otsuka T, Yano H, Ozaki K, Tsuchishima M, Tsutsumi M, Arisawa T, Cytokine 2010 51 2 173 177 10.1016/j.cyto.2010.05.003 20621719
25. Functional promoter polymorphisms of macrophage migration inhibitory factor in peptic ulcer diseases. Shiroeda H, Tahara T, Shibata T, Nakamura M, Yamada H, Nomura T, Hayashi R, Saito T, Fukuyama T, Otsuka T, Yano H, Ozaki K, Tsuchishima M, Tsutsumi M, Arisawa T, Int J Mol Med 2010 26 5 707 711 20878093
26. A MIF haplotype is associated with the outcome of patients with severe sepsis: a case control study. Lehmann LE, Book M, Hartmann W, Weber SU, Schewe JC, Klaschik S, Hoeft A, Stüber F, J Transl Med 2009 7 100 10.1186/1479-5876-7-100 19941661
27. Macrophage migration inhibitory factor (MIF) gene polymorphisms are associated with increased prostate cancer incidence. Meyer-Siegler KL, Vera PL, Iczkowski KA, Bifulco C, Lee A, Gregersen PK, Leng L, Bucala R, Genes and immunity 2007 8 8 646 52 10.1038/sj.gene.6364427 17728788 (Pubitemid 350238434)
28. Functional promoter polymorphisms of the macrophage migration inhibitory factor gene in gastric carcinogenesis. Arisawa T, Tahara T, Shibata T, Nagasaka M, Nakamura M, Kamiya Y, Fujita H, Yoshioka D, Arima Y, Okubo M, Hirata I, Nakano H, De la Cruz V, Oncology reports 2008 19 223 8 18097599 (Pubitemid 351176153)
29. The association between MIF-173 GC polymorphism and prostate cancer in southern Chinese. Ding GX, Zhou SQ, Xu Z, Feng NH, Song NH, Wang XJ, Yang J, Zhang W, Wu HF, Hua LX, J Surg Oncol 2009 100 2 106 110 10.1002/jso.21304 19475570
30. The MIF -173G/C polymorphism and risk of childhood acute lymphoblastic leukemia in a Chinese population. Xue Y, Xu H, Rong L, Lu Q, Li J, Tong N, Wang M, Zhang Z, Fang Y, Leuk Res 2010 34 10 1282 1286 10.1016/j.leukres.2010.03.030 20447688
31. The MIF-173G/C polymorphism does not contribute to prednisone poor response in vivo in childhood acute lymphoblastic leukemia. Ziino O, D'Urbano LE, Benedetti FD, Conter V, Barisone E, Rossi GD, Basso G, Aric M, Leukemia 2005 19 12 2346 2347 10.1038/sj.leu.2403973 16208413 (Pubitemid 41741636)
32. Clinical utility of serum macrophage migration inhibitory factor in men with prostate cancer as a novel biomarker of detection and disease progression. Muramaki M, Miyake H, Yamada Y, Hara I, Oncology reports 2006 15 253 7 16328065
33. The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Fingerle-Rowson G, Petrenko O, Metz CN, Forsthuber TG, Mitchell R, Huss R, Moll U, Muller W, Bucala R, Proc Natl Acad Sci USA 2003 100 16 9354 9 10.1073/pnas.1533295100 12878730 (Pubitemid 37033932)
34. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. Mitchell RA, Metz CN, Peng T, Bucala R, J Biol Chem 1999 274 25 18100 6 10.1074/jbc.274.25. 18100 10364264 (Pubitemid 29283341)
35. Expression of macrophage migration inhibitory factor relates to survival in high-grade osteosarcoma. Han I, Lee MR, Nam KW, Oh JH, Moon KC, Kim HS, Clin Orthop Relat Res 2008 466 9 2107 2113 10.1007/s11999-008-0333-1 18563508
36. Crosstalk between Medulloblastoma Cells and Endothelium Triggers a Strong Chemotactic Signal Recruiting T Lymphocytes to the Tumor Microenvironment. Salsman VS, Chow KKH, Shaffer DR, Kadikoy H, Li XN, Gerken C, Perlaky L, Metelitsa LS, Gao X, Bhattacharjee M, Hirschi K, Heslop HE, Gottschalk S, Ahmed N, PLoS One 2011 6 5 20267 10.1371/journal.pone.0020267 21647415
37. On estimating the relation between blood group and disease. Woolf B, Ann Hum Genet 1955 19 4 251 253 10.1111/j.1469-1809.1955.tb01348.x 14388528
38. Quantitative synthesis in systematic reviews. Lau J, Ioannidis JP, Schmid CH, Ann Intern Med 1997 127 9 820 826 9382404 (Pubitemid 27465551)
39. Measuring inconsistency in meta-analyses. Higgins JPT, Thompson SG, Deeks JJ, Altman DG, BMJ 2003 327 7414 557 560 10.1136/bmj.327.7414.557 12958120 (Pubitemid 37088507)
40. meta: Meta-Analysis with R. Schwarzer G, 2010 http://CRAN.R-project.org/ package=meta [R package version 1.6-1]
41. Conducting meta-analyses in R with the metafor package. Viechtbauer W, Journal of Statistical Software 2010 36 3 1 48